ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VAXX Vaxxinity Inc

0.1111
0.00 (0.00%)
31 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Vaxxinity Inc VAXX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.00 0.00% 0.1111 10:00:00
Open Price Low Price High Price Close Price Previous Close
0.1111 0.1111
more quote information »

Recent News

Date Time Source Heading
10/5/202406:24EDGAR2Form 15-12G - Securities registration termination [Section..
10/5/202406:09EDGAR2Form DEF 14C - Other definitive information statements
20/4/202408:53GLOBEVaxxinity Issues Shareholder Letter
20/4/202406:27GLOBEVaxxinity Announces Intention to Voluntarily Delist and..
29/3/202400:23GLOBEVaxxinity to Present Clinical Data at the Annual Academy of..
28/3/202407:41GLOBEVaxxinity Reports Fourth Quarter and Full-Year 2023..
08/3/202402:32GLOBEVaxxinity Announces Positive Target Engagement Data from..
16/2/202408:15EDGAR2Form 8-K - Current report
16/2/202400:00GLOBEVaxxinity’s Cholesterol Vaccine Candidate Successfully..
14/2/202400:00GLOBEVaxxinity to Present Clinical and Preclinical Pipeline Data..
13/2/202409:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202409:02EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202400:00GLOBEVaxxinity Announces Research Collaboration on Active..
19/1/202400:00GLOBEVaxxinity Announces Collaboration on Space Medicine Research..
04/1/202400:00GLOBEVaxxinity to Present at the 2024 J.P. Morgan Healthcare..
02/12/202302:30EDGAR2Form 8-K - Current report
01/12/202309:03EDGAR2Form 144 - Report of proposed sale of securities
01/12/202308:54EDGAR2Form 144 - Report of proposed sale of securities
30/11/202309:13EDGAR2Form 144 - Report of proposed sale of securities
30/11/202309:10EDGAR2Form 144 - Report of proposed sale of securities
22/11/202308:21EDGAR2Form 144 - Report of proposed sale of securities
22/11/202308:20EDGAR2Form 144 - Report of proposed sale of securities
14/11/202310:50GLOBEVaxxinity to Present at Upcoming November Medical and..
09/11/202300:30GLOBEVaxxinity Reports Third Quarter 2023 Financial Results and..
08/11/202323:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
04/11/202307:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202307:33EDGAR2Form 144 - Report of proposed sale of securities
05/10/202307:24EDGAR2Form 144 - Report of proposed sale of securities
29/9/202306:15EDGAR2Form 8-K - Current report
23/9/202306:16EDGAR2Form 144 - Report of proposed sale of securities
23/9/202306:12EDGAR2Form 144 - Report of proposed sale of securities
29/8/202322:00GLOBEVaxxinity to Present at Upcoming Investor Conferences in..
21/8/202314:15EDGAR2Form EFFECT - Notice of Effectiveness
10/8/202322:00GLOBEVaxxinity Announces Publication of UB-311 Safety,..
09/8/202322:00GLOBEVaxxinity Reports Second Quarter 2023 Financial Results and..
09/8/202321:31EDGAR2Form S-3 - Registration statement under Securities Act of..
09/8/202321:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28/7/202306:30GLOBEVaxxinity Appoints Peter Powchik, M.D., to Executive Vice..
28/7/202306:04EDGAR2Form 8-K - Current report
17/7/202322:00GLOBEVaxxinity Demonstrates Target Engagement of Toxic..
22/6/202322:00GLOBEVaxxinity Announces UB-312 Successfully Met Primary..